Please use this identifier to cite or link to this item:
|Title:||Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach||Authors:||Salto-Tellez, M.
Tyrosine kinase inhibitor
|Issue Date:||Oct-2011||Citation:||Salto-Tellez, M., Tsao, M.-S., Shih, J.-Y., Thongprasert, S., Lu, S., Chang, G.-C., Au, J.S.-K., Chou, T.-Y., Lee, J.-S., Shi, Y.-K., Radzi, A., Kang, J.-H., Kim, S.-W., Tan, S.-Y., Yang, J.C.-H. (2011-10). Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach. Journal of Thoracic Oncology 6 (10) : 1663-1669. ScholarBank@NUS Repository. https://doi.org/10.1097/JTO.0b013e318227816a||Abstract:||Background: Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols. Methods: A consensus meeting was held involving expert oncologists, pulmonologists, and pathologists to discuss the current status and variations in EGFR mutation testing of NSCLC across Asia and to recommend a standard clinical and laboratory testing approach for future use. Results: Currently, EGFR mutation tests are only routinely performed in some East Asian countries and medical centers. The consensus recommendation was to perform the test in all newly diagnosed patients with advanced stage nonsquamous lung cancer and some squamous patients with clinical features associated with higher prevalence of EGFR mutations. To increase the sensitivity and specificity of the EGFR mutation tests, tissue acquisition and pretest sample evaluation are important steps in addition to standardization of the EGFR mutation test methodology. Conclusion: A standardized EGFR mutation testing protocol is an essential step toward realization of personalized medicine in East Asian NSCLC treatment. © 2011 by the International Association for the Study of Lung Cancer.||Source Title:||Journal of Thoracic Oncology||URI:||http://scholarbank.nus.edu.sg/handle/10635/109248||ISSN:||15560864||DOI:||10.1097/JTO.0b013e318227816a|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 12, 2021
WEB OF SCIENCETM
checked on Oct 12, 2021
checked on Oct 14, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.